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Efficacy of misoprostol for the treatment of 
postpartum hemorrhage: current knowledge 
and implications for health care planning
Ndola Prata
Karen Weidert
Bixby Center for Population, Health 
and Sustainability, School of Public 
Health, University of California at 
Berkeley, Berkeley, CA, USA
Background: A myriad of interventions exist to treat postpartum hemorrhage (PPH), ranging 
from uterotonics and hemostatics to surgical and aortic compression devices. Nonetheless, PPH 
remains the leading cause of maternal mortality worldwide. The purpose of this article is to 
review the available evidence on the efficacy of misoprostol for the treatment of primary PPH 
and discuss implications for health care planning.
Data and methods: Using PubMed, Web of Science, and GoogleScholar, we reviewed the 
literature on randomized controlled trials of interventions to treat PPH with misoprostol and 
non-randomized field trials with controls. We discuss the current knowledge and implications 
for health care planning, especially in resource-poor settings.
Results: The treatment of PPH with 800 µg of misoprostol is equivalent to 40 IU of intrave-
nous oxytocin in women who have received oxytocin for the prevention of PPH. The same 
dose might be an option for the treatment of PPH in women who did not receive oxytocin for 
the prevention of PPH and do not have access to oxytocin for treatment. Adding misoprostol 
to standard uterotonics has no additional benefits to women being treated for PPH, but the 
beneficial adjunctive role of misoprostol to conventional uterotonics is important in reducing 
intra- and postoperative hemorrhage during cesarean section.
Conclusion: Misoprostol is an effective uterotonic agent in the treatment of PPH. Clinical 
guidelines and treatment protocols should be updated to reflect the current knowledge on the 
efficacy of misoprostol for the treatment of PPH with 800 µg sublingually.
Keywords: PPH treatment, uterotonics, low-resource settings, cesarean section, retained placenta
Introduction
The world has witnessed reductions in maternal deaths in the past decade. Kassebaum 
et al1 reported that the annual rate of change in the maternal mortality ratio was greater 
than −1% between 2003 and 2013, with the most substantial improvement from 2012 
to 2013 at −3.3%. Many of the global gains in reducing maternal mortality can be 
attributed to developments in preventing and treating postpartum hemorrhage (PPH). 
In fact, the biggest absolute reduction was in maternal deaths due to hemorrhage.
Yet, PPH remains the most common cause of maternal death globally2 and has 
persisted in low-income countries with little change since 1990.1 This is in part due to 
the prevalence of home deliveries and limited access to life-saving uterotonic drugs in 
these countries.3–5 Meanwhile, there is also evidence that the rate of retained placenta 
and PPH is increasing in higher-income countries.6,7
PPH is often associated with the failure of the uterus to contract after delivery and 
categorized as blood loss of 500 mL or more following vaginal delivery or 1,000 mL 
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after cesarean delivery.8,9 PPH is categorized as primary if it 
occurs within 24 hours of delivery and secondary if excessive 
blood loss occurs at 24 hours or more after delivery. The 
reality is that most cases are primary PPH and the time from 
beginning to death is considerably shorter than other major 
obstetric complications. Two factors have been identified 
as significantly affecting the potential for death from PPH. 
First, the initial hemoglobin (Hb) level of a woman affects 
her survival rate from PPH.10 The World Health Organization 
(WHO) defines anemia in pregnancy as Hb level ,11 g/dL 
and reported that anemia among pregnant women in develop-
ing countries exceeds 50%.11 Recently, a strong correlation 
was found between low Hb (Hb ,10) and the risk of PPH, as 
well as an association between severe anemia and emergency 
hysterectomy.12 Anemia can be detected during pregnancy, 
but early detection and treatment are not always promising 
in settings where limited access to quality antenatal care is 
further compounded by dietary deficiencies and concurrent 
medical disorders affecting iron absorption.12–14 The second 
factor that has been identified as contributing to mortality 
rates from PPH has more levers for influence, as it relates 
to access to a hospital with functioning facilities for the 
management of PPH, including blood banks and staff trained 
to diagnose and treat PPH. Although effective tools for the 
prevention and treatment of PPH are available, most are not 
feasible or available for use in the resource-poor countries, 
where many births still occur at home with untrained birth 
attendants.10 Meanwhile, the management of PPH is further 
complicated by timely diagnosis.10 Underestimation of 
blood loss by 100–150 mL is common when applying visual 
estimation.15 A study in 13 European countries showed that 
the use of a blood collector bag has not significantly reduced 
the rate of PPH, likely due to larger challenges in the manage-
ment of PPH.16 However, better accuracy in the measurement 
of postpartum blood loss in developing countries might be an 
important first step toward improving case management.17
A recent multinational study led by the WHO to explore 
clinical practices, risks, and maternal outcomes associ-
ated with PPH included 275,000 births in 28 low- and 
middle-income countries. Of all the women included in 
the analysis, 95.3% received an uterotonic prophylaxis and 
1.2% of women reported PPH; with the overall PPH death 
rate of 38 per 100,000 births. Not only is uterotonic treat-
ment of PPH important in the reduction of adverse maternal 
outcomes but it can help avert more medical interventions, 
including the administration of intravenous (IV) fluids, addi-
tional drug therapy, blood transfusion, and surgery.18
The role of misoprostol, a prostaglandin E1 analog, in the 
prevention and treatment of PPH has evolved over time due 
to its long shelf life and multiple routes of administration, 
which make it more suitable for low-resource settings with 
limited skilled providers.19,20 As early as 2007, researchers 
were supporting the use of misoprostol for treating PPH in 
cases where other treatments are not available or not working, 
yet treating PPH in the community with misoprostol has 
lagged behind its widespread prophylactic use.9,21
The purpose of this article is to review the available 
evidence on the efficacy of misoprostol for the treatment of 
primary PPH. A brief historical perspective on the use of 
misoprostol for PPH and its potential role in treatment is pre-
sented as well as implications for management guidelines and 
health care planning, especially for low-income countries.
Data and methods
We first searched the Cochrane Database of Systematic 
Reviews for the most recent review of misoprostol for the 
treatment of PPH. We then searched PubMed for the lit-
erature on randomized controlled trials (RCTs) of interven-
tions to treat PPH with misoprostol and reviewed relevant 
manuscripts not included in the most recent systematic 
review. Finally, we searched PubMed, Web of Science, and 
GoogleScholar for non-randomized field trials of interven-
tions to treat PPH with misoprostol. The search covered the 
period from 2000 until 2015. The following search terms and 
various combinations were used: “postpartum hemorrhage”, 
“PPH”, “PPH treatment with misoprostol”, “misoprostol”, 
“randomized controlled trial”, “RCT”, “operations research”, 
“field trial”, “interventions to treat PPH”, “vaginal delivery”, 
“cesarean section”, and “retained placenta”.
Evidence on efficacy is based on the results from RCTs 
against either placebo or another uterotonic agent with or 
without active management of the third stage of labor with an 
uterotonic agent. Since we found only seven randomized con-
trolled studies, we assess them individually. The last systematic 
review of misoprostol to treat PPH was published in 2005 and 
included only three of the seven reviewed RCTs. Even though it 
is not the primary aim of this review, we report on the efficacy 
of misoprostol for two conditions commonly associated with 
PPH, cesarean section and retained placenta. For these two 
conditions, we started with the more recent systematic review 
and meta-analysis, or Cochrane review published since 2000, 
and then reviewed individual RCT studies published after the 
systematic review. Results from non-randomized studies with 
controls or cohort studies are also reviewed. Current perspec-
tives on PPH treatment are discussed including advances in 
drug regimens, gaps in current knowledge regarding PPH 
treatment with misoprostol, and challenges and opportunities 
for large-scale implementation in low-income countries.
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Results
Misoprostol for the treatment of PPH
Over the past decade, key women’s health organizations have 
promoted the inclusion of misoprostol for the treatment of 
PPH. As early as 2006, the International Confederation of 
Midwives and the International Federation of Gynecology 
and Obstetrics (FIGO) recommended that misoprostol for 
the treatment of PPH may be appropriate for use in low-
resource settings as a stand-alone treatment, in combination 
with oxytocin, and as a last resort for PPH treatment.22 At the 
same time, the American Congress of Obstetricians and 
Gynecologists included misoprostol in the list of uterotonics 
to be used as the first-line treatment for hemorrhage in the 
event of decreased uterine atony.23 A few years later, the 
Royal College of Obstetricians and Gynecologists agreed 
that misoprostol may be an appropriate alternative for PPH 
treatment in settings, where parenteral prostaglandins are 
not available or where there are contraindications.24 In 2012, 
FIGO published its guidelines for the treatment of PPH 
with misoprostol: “one dose of misoprostol 800 µg sublin-
gually is indicated for the treatment of PPH when 40 IU IV 
oxytocin is not immediately available (irrespective of the 
prophylactic measures)”.25
In 2014, the Cochrane collaboration published a 
systematic review on the treatment for primary PPH.26 
The review assessed the effectiveness and safety of any 
intervention used for the treatment of PPH. Of the ten 
RCTs reviewed spanning 4,052 women, seven investigated 
misoprostol in doses varying from 600 µg to 1,000 µg, 
using various routes of administration, including a combi-
nation of sublingual and rectal. The finding that seven out 
of ten studies were assessing the efficacy of misoprostol 
alone suggests that the role of misoprostol has been one 
of the most studied interventions in the treatment of PPH 
in recent decades. However, it was not until April 2015 
that misoprostol was added to Essential Medicines WHO 
Model List (EML) for the treatment of PPH. The EML now 
recommends the use of misoprostol for the “prevention 
and treatment of PPH where oxytocin is not available or 
cannot be safely used”.27
Evidence of efficacy of misoprostol for 
the treatment of PPH
Table 1 presents the results from all the published RCTs on 
the use of misoprostol for the treatment of primary PPH after 
vaginal deliveries. The last systematic review of misopros-
tol to treat PPH was published in 2005 and included three 
RCTs.28 However, given that only seven trials were available, 
we decided to show them individually in Table 1. RCTs have 
used multiple dose regimens and routes, in addition to con-
trolling against placebo or another conventional uterotonic, 
oxytocin, and/or ergometrine. The first RCT was published 
in 2001 comparing 800 mg of misoprostol rectally to 5 IU 
oxytocin and 500 µg ergometrine intramuscular plus 10 IU 
oxytocin diluted in 500 mL normal saline IV infusion. Results 
from a relatively small sample size (n=32 in each arm) were 
promising, indicating that misoprostol is an effective thera-
py.29 In 2004, Hofmeyr et al30 published a placebo-controlled 
trial testing a high-dose misoprostol, but the study was under-
powered to show significant differences. In the same year, a 
study by Walraven et al31 combined oral (200 µg) and sub-
lingual (400 µg) routes of misoprostol and also showed the 
therapeutic potential of misoprostol against a placebo. Four 
years later, an RCT in Pakistan attempted to ascertain whether 
sublingual misoprostol had additional benefits to a standard 
oxytocin regimen. Although significant reductions in blood 
loss in the misoprostol group were reported, the study did not 
reach the intended sample size due to much lower PPH rate 
than expected.32 However, it was not until 2010 that pivotal 
evidence on the therapeutic potential of misoprostol became 
available from three RCTs. In a double-blind non-inferiority 
trial, Blum et al demonstrated that 800 µg of sublingual 
misoprostol is clinically equivalent to 40 IU IV oxytocin 
in women who have received prophylactic oxytocin during 
the third stage of labor. However, while the time to cessa-
tion and additional blood loss of 300 mL and 500 mL was 
equivalent, the number of women in the misoprostol group 
with .1,000 mL of additional blood loss was significantly 
higher (relative risk [RR]: 3.6; 95% confidence interval [CI]: 
1.02–12.88). The women in the misoprostol group were 
also more likely to undergo intrauterine clinical exploration 
under anesthesia (RR: 1.66; 95% CI: 1.00–2.76).33 Results 
from a similar trial, but among women who have not been 
exposed to oxytocin during the third stage of labor, showed 
that misoprostol is slightly inferior to oxytocin.34 Authors 
conclude that in the absence of oxytocin, misoprostol might 
be an appropriate first-line treatment for PPH. The third RCT, 
published in 2010, assessed whether 600 µg of sublingual 
misoprostol could be used as an adjunct therapy to standard 
uterotonics. Results showed that when compared to a placebo, 
misoprostol does not offer additional benefits.35
Table 2 shows the results from three non-randomized 
cohort studies with controls. These studies attempted to 
demonstrate application in home and hospital births. The 
study by Prata et al,36 the only community-based study with 
controls for the treatment of PPH, used a high dose (1,000 µg) 
of rectal misoprostol and demonstrated the potential use of 
misoprostol for PPH treatment in settings where women were 
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not exposed to conventional uterotonics during the third stage 
of labor. In fact, Winikoff et al’s34 RCT findings, although 
with a lower dose and different route, confirmed the value of 
misoprostol in settings where oxytocin is not available. The 
use of high-dose rectal misoprostol was also assessed as an 
adjunct therapy to oxytocin compared to ergometrine using 
a retrospective cohort study design.37 Results showed no 
significant differences between the two groups. Based on the 
results from the 2010 RCT, we now know that misoprostol 
has no adjunct therapeutic properties.35 A cohort study in 
three Nigerian hospitals showed that 800 µg of sublingual 
misoprostol was efficacious in stopping bleeding within 
20 minutes of use among women diagnosed with PPH from 
uterine atony and not exposed to uterotonics during the third 
stage of labor, suggesting that the application of results of the 
2010 RCT in clinical practice produces intended outcomes. 
Misoprostol stopped bleeding in 85% of the PPH cases, the 
remaining needed additional uterotonics.38
The safety profile of misoprostol in obstetrics has long 
been established and is linked to the pharmacokinetic pro-
file of E2 prostaglandin analog.39 In RCTs, misoprostol 
administered in treatment doses shows increased RR of side 
effects when compared to placebo. Although side effects 
were reported as transient and occurring in a small group 
of women, pooled data from a Cochrane review show aver-
age increases in vomiting (RR: 1.84; 95% CI: 1.16–2.95), 
shivering (RR: 2.25; 95% CI: 1.76–2.88), pyrexia of 38°C 
(RR: 3.12; 95% CI: 2.66–3.67), and pyrexia of 40°C or more 
(RR: 13.58; 95% CI: 4.93–37.44).26
Other conditions around labor and 
delivery associated with PPH
The use of misoprostol in intra- and postoperative hemor-
rhage, as well as in retained placenta, has been investigated. 
Results from a systematic review and meta-analysis evaluat-
ing the efficacy and safety of misoprostol for reducing intra- 
and postoperative hemorrhage showed that misoprostol 
combined with oxytocin seems to be more efficacious than 
oxytocin alone.40 The systematic review included 17 studies 
totaling 3,174 women. Seven studies assessed misoprostol 
vs oxytocin and seven assessed misoprostol plus oxytocin 
vs oxytocin alone. Subsequent RCTs found similar results 
when comparing misoprostol and oxytocin to oxytocin alone 
during cesarean delivery in women at risk of PPH.41,42
A Cochrane review of prostaglandins for the management 
of retained placenta involving 244 women, of whom 194 
received a dose of 800 µg misoprostol, showed that prostaglan-
dins were not superior compared to placebo. No statistically 
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significant differences were found in the manual removal of 
placenta, severe PPH, need for blood transfusion, or other 
interventions.43 However, the authors noted that the quality 
of the evidence was low and called for much larger and suf-
ficiently powered studies to make recommendations.
Implications for management 
guidelines and health care planning
Although RCTs and non-randomized trials have used 
different doses and routes of administration, current evidence 
points to an optimal and effective dose regimen of 800 µg 
of sublingual misoprostol for the treatment of PPH, which 
was endorsed by FIGO.25 The safety profile of this dose and 
route is sufficient, but prostaglandin-related side effects such 
as shivering and vomiting may occur.26
Misoprostol’s clinical equivalence to 40 IU IV oxytocin, 
when used for the treatment of PPH in women who have 
received a prophylactic dose of oxytocin during the third 
stage of labor, provides unique opportunities for low-resource 
settings. Where labor wards are ill-equipped to provide suf-
ficient monitoring and quality IV infusion, service providers 
can use intramuscular oxytocin during the third stage of labor 
and sublingual misoprostol if a PPH diagnosis is established 
without hesitation. In addition, given the longer shelf life of 
misoprostol and relatively better stability in field conditions,39 
health service planners, particularly those responsible for 
drug procurement, can adjust forecasting and purchasing of 
the drug assuming all estimated primary PPH cases will be 
treated with misoprostol, making it the first-line treatment.
Current evidence shows that in the absence of oxytocin 
prophylaxis during the third stage of labor, the drug of choice 
for the treatment of PPH should be 40 IU IV oxytocin. How-
ever, in settings where oxytocin is not available, sublingual 
misoprostol is an appropriate first-line treatment. This finding 
is of significance for settings where a large number of women 
deliver at home without a skilled provider or with a minimally 
trained one, as well as in settings where delivery begins at 
home and access to health facilities for referral when PPH 
is identified is limited due to the lack of transportation, road 
security at night, and other issues.3
Contrary to expectations based on the evidence prior to 
2010, findings from a multicenter RCT do not support the 
use of misoprostol in addition to standard uterotonics (oxy-
tocin or ergometrine) for the treatment of primary PPH after 
vaginal deliveries.35 However, RCTs have demonstrated the 
opposite for cesarean deliveries.40–42 Thus, the adjunct role 
of misoprostol to conventional uterotonics is important in 
reducing intra- and postoperative hemorrhage.
In summary, current evidence on misoprostol efficacy is 
sufficient to move programs forward such that low-income 
countries, the ones with highest share of PPH-attributed 
burden of disease, can benefit from the ease of administra-
tion and storage of the drug. However, it is also in these 
contexts where the management of PPH cases is more chal-
lenging, despite knowledge of drug efficacy. For example, 
the efficacy from clinical trials assumes relatively accurate 
blood loss measurement, leading to a specific point in time 
when treatment is administered. Thus, standardizing clinical 
protocols with culturally appropriate ways to measure blood 
loss after delivery could increase program effectiveness for 
the treatment of PPH. Task shifting or sharing with provid-
ers at lower-level health centers and health posts, including 
community health workers, should also be considered, 
especially when referrals to health facilities are difficult. 
In many countries, where access to misoprostol for PPH is 
being scaled up,44 providers could benefit from learning not 
just about prevention but also about the treatment for PPH, 
including clinical officers providing emergency cesarean 
sections in rural or district hospitals. Other ways to potentially 
increase program effectiveness to treat PPH in women who 
deliver at home would certainly include the use of community 
health workers and/or traditional birth attendants trained in 
the recognition of PPH and administration of misoprostol. 
However, more evidence in this area is still needed.
A Cochrane review with the objective of determining the 
safety and effectiveness of a system for advanced distribution 
of misoprostol for the prevention and treatment of PPH found 
insufficient evidence to support such a system.45 The review 
identified three studies, and none of them met the inclusion 
criteria – randomized or quasi RCTs. Thus, the conclusion 
is based on the lack of evidence rather than results from 
existing evidence. However, given the current knowledge 
of PPH-attributed mortality and the role of misoprostol to 
treat PPH, a randomized placebo-controlled experiment 
for advance distribution at community level might pose 
ethical concerns.
The comparison of misoprostol to placebo or to conven-
tional uterotonics would allow programs to make informed 
decisions about the realm of interventions that are possible 
to implement in each setting according to provider level and 
health care system capacity. However, one important ques-
tion still remains: can misoprostol be given for the treatment 
of PPH after its use for prevention during the third stage of 
labor? In addition, even though conventional uterotonics 
are more commonly used, what is the relative contribution 
of misoprostol compared to other interventions for PPH 
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treatment, such as the non-pneumatic antishock garment, 
hemostatic drugs, and surgical interventions? A review of 
these interventions concluded that more evidence is needed, 
including the best ways to treat women who do not respond 
to uterotonics.26
Conclusion
Misoprostol is an effective therapy for primary PPH. Clinical 
guidelines and treatment protocols should be updated to 
reflect the current knowledge on the efficacy of 800 µg 
sublingual misoprostol for the treatment of PPH. However, 
improvements in PPH treatment, regardless of the uterotonic, 
should start with a timely and correct diagnosis that can 
lead to an appropriate case management. Women with prior 
exposure to prophylactic oxytocin, as well as those without 
exposure to oxytocin and in settings where oxytocin is not 
available, could all benefit from the therapeutic properties 
of this drug. Women undergoing cesarean section and at risk 
of PPH could also benefit from the efficacy of misoprostol 
in conjunction with oxytocin.
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